Introduction: Neuroinflammation and synaptic degeneration are major neuropathological hallmarks in Alzheimer's disease (AD). Neurogranin and YKL-40 in cerebrospinal fluid (CSF) are newly discovered markers indicating synaptic damage and microglial activation, respectively.
Methods: CSF samples from 95 individuals including 39 patients with AD dementia (AD-D), 13 with mild cognitive impairment (MCI) due to AD (MCI-AD), 29 with MCI not due to AD (MCI-o) and 14 patients with non-AD dementias (non-AD-D) were analyzed for neurogranin and YKL-40.
Results: Patients with dementia or MCI due to AD showed elevated levels of CSF neurogranin (p < 0.001 for AD-D and p < 0.05 for MCI-AD) and YKL-40 (p < 0.05 for AD-D and p = 0.15 for MCI-AD) compared to mildly cognitively impaired subjects not diagnosed with AD. CSF levels of neurogranin and YKL-40 did not differ between MCI not due to AD and non-AD dementias. In AD subjects no correlation between YKL-40 and neurogranin was found. The CSF neurogranin levels correlated moderately with tau and p-tau but not with Aβ42 or the MMSE in AD samples. No relevant associations between YKL-40 and MMSE or the core AD biomarkers, Aβ42, t-tau and p-tau were found in AD subjects.
Conclusions: Neurogranin and YKL-40 are promising AD biomarkers, independent of and complementary to the established core AD biomarkers, reflecting additional pathological changes in the course of AD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690296 | PMC |
| http://dx.doi.org/10.1186/s13195-015-0161-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuroinflammation in Parkinson's disease: A study with [C]PBR28 PET and cerebrospinal fluid markers.
Parkinsonism Relat Disord
January 2025
Turku PET Centre, University of Turku, Turku, Finland; Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland.
Objective: To investigate neuroinflammation in Parkinson's disease (PD) with [C]PBR28 positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers, and the relationship to dopaminergic functioning measured with 6-[F]-fluoro-L-dopa ([F]FDOPA) PET.
Methods: The clinical cohort consisted of 20 subjects with PD and 51 healthy controls (HC). All HC and 15 PD participants underwent [C]PBR28 High Resolution Research Tomograph (HRRT) PET for the quantitative assessment of cerebral binding to the translocator protein (TSPO), a neuroinflammation marker.
Axonal damage and inflammation response are biological correlates of decline in small-world values: a cohort study in autosomal dominant Alzheimer's disease.
Brain Commun
October 2024
Alzheimer center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Programme Neurodegeneration, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HZ Amsterdam, The Netherlands.
Article Synopsis
- * In Alzheimer's disease, these networks become more chaotic, as indicated by a drop in the small-world coefficient, a change linked to cognitive decline throughout the disease's progression.
- * Our study examined the relationship between 10 cerebrospinal fluid protein biomarkers and small-world coefficients in Alzheimer's mutation carriers and non-carriers, finding that certain protein abnormalities indicate early changes in grey matter networks, while markers for inflammation and axonal injury correlate with declining small-world values.
Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: an update of the literature.
Expert Rev Neurother
November 2024
Division of Molecular Medicine, Ruder Boskovic Institute, Zagreb, Croatia.
Article Synopsis
- The use of cerebrospinal fluid (CSF) biomarkers is becoming crucial for diagnosing Alzheimer's disease (AD) and monitoring therapy responses due to advancements in treatment strategies for neurodegenerative diseases.
- This review examines key neurodegeneration markers to differentiate AD patients from healthy individuals and those with mild cognitive impairment, focusing on various biological markers related to amyloid processing, neurofibrillary tangles, neuroinflammation, and neuroaxonal injury.
- Core CSF biomarkers like Aβ, t-tau, and p-tau181 are recommended for accurate AD diagnosis and tracking disease progression, along with emerging markers related to synaptic dysfunction and neuroinflammation that need further validation for clinical application.
Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease.
Alzheimers Dement (N Y)
August 2024
Amylyx Pharmaceuticals, Inc. Cambridge Massachusetts USA.
Introduction: Sodium phenylbutyrate and taurursodiol (PB and TURSO) is hypothesized to mitigate endoplasmic reticulum stress and mitochondrial dysfunction, two of many mechanisms implicated in Alzheimer's disease (AD) pathophysiology.
Methods: The first-in-indication phase 2a PEGASUS trial was designed to gain insight into PB and TURSO effects on mechanistic targets of engagement and disease biology in AD. The primary clinical efficacy outcome was a global statistical test combining three endpoints relevant to disease trajectory (cognition [Mild/Moderate Alzheimer's Disease Composite Score], function [Functional Activities Questionnaire], and total hippocampal volume on magnetic resonance imaging).
KLOTHO KL-VS heterozygosity is associated with diminished age-related neuroinflammation, neurodegeneration, and synaptic dysfunction in older cognitively unimpaired adults.
Alzheimers Dement
August 2024
Wisconsin Alzheimer's Disease Research Center and Department of Geriatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Introduction: We examined whether the aging suppressor KLOTHO gene's functionally advantageous KL-VS variant (KL-VS heterozygosity [KL-VS]) confers resilience against deleterious effects of aging indexed by cerebrospinal fluid (CSF) biomarkers of neuroinflammation (interleukin-6 [IL-6], S100 calcium-binding protein B [S100B], triggering receptor expressed on myeloid cells [sTREM2], chitinase-3-like protein 1 [YKL-40], glial fibrillary acidic protein [GFAP]), neurodegeneration (total α-synuclein [α-Syn], neurofilament light chain protein), and synaptic dysfunction (neurogranin [Ng]).
Methods: This Alzheimer disease risk-enriched cohort consisted of 454 cognitively unimpaired adults (M= 61.5 ± 7.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!